You are here: Industry Insights > Market News > Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech

firstwordpharmaJuly 13, 2021

Tag: Covaxin , COVID-19 vaccine , WHO

Favorites

Bharat Biotech on Monday said it has submitted all documents required for the emergency use listing of its COVID-19 vaccine Covaxin to the World Health Organization (WHO), as reported by The Economic Times.

Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech

Last week, WHO chief scientist Soumya Swaminathan said the agency is likely to take a decision on Covaxin’s emergency use listing within four to six weeks.

"All documents required for Emergency Use Listing (EUL) of Covaxin have been submitted to WHO as of 9th July. The review process has now commenced with the expectation that we will receive EUL from WHO at the earliest," tweeted Bharat chairman Krishna Ella.

Previous:Pregnant women to receive Moderna COVID-19 vaccine in clinical trial

Next:Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Herbal products wholesaler Supply Thyme Extract Thymol

Wholesale Price Women's Capsules

Safflower (Whole/ Cut/ Slice)

Wholesale High Quality L-Theanine Powder

Hot selling Wholesale bulk price METHYL MYRISTATE CAS 124-10-7 with sample in stock

Dong Quai (Whole/ Cut/ Slice)

Hot selling Wholesale bulk price Ammonium lauryl sulfate/ALS Cosmetic grade CAS 2235-54-3

Wholesale Price Turkesterone Capsules

Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard and Produce

100% Natural Thymol wholesaler Supply Thyme Extract Thymol in Essential Distillation with Fast Deliv

Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>